MondayMar 11, 2024 2:11 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial Application (“CTA”) for its planned phase-1b clinical trial. According to the announcement, the trial will focus on evaluating the safety and efficacy of unbuzzd(TM) in healthy volunteers in an induced state of alcohol intoxication. The application is the first step in receiving approval to begin the trial; the application will be reviewed by an Australian human ethics review committee (“HREC”). Pending approval, the company anticipates beginning to…

Continue Reading

TuesdayMar 05, 2024 3:39 pm

PsychedelicNewsBreaks – Mushrooms Inc. (MSRM) Announces Latest Product Launches, Development Collaboration in Germany

Mushrooms (OTC: MSRM), a developing leader in biotechnology and sustainable healthcare innovation using mushrooms and mycelium, today announced a suite of strategic initiatives aimed at transforming the healthcare landscape. These efforts, which underscore Mushrooms Inc.’s commitment to innovation, sustainability and the advancement of global health, include the launch of two groundbreaking health supplements, LONGEVITY and SPORT+, as well as the exploration of a development collaboration with a renowned scientific team in Germany. “We are at an exciting juncture in our journey,” said Mushrooms Inc. CEO Kimberly Carlson. “Our latest product launches and the collaboration in Germany are pivotal steps towards…

Continue Reading

TuesdayMar 05, 2024 1:53 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North America. Represented by its senior research and clinical development team and co-authored by several of its esteemed scientific advisors, FSD shared the results of its phase 1 clinical study. The results were displayed in a…

Continue Reading

WednesdayFeb 28, 2024 1:20 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced a debt settlement. According to the announcement, the company’s board of directors approved the settlement of $637,650 owed to arm's length creditors through issuing 545,000 Class B subordinate voting shares in the capital of the corporation; the shares were issued at $1.17 per share. The board also approved the granting of 55,000 restricted share units (“RSUs”) to consultants of the company according to FSD Pharma’s equity incentive plan, with each RSU good for the acquisition of…

Continue Reading

MondayFeb 26, 2024 1:49 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and its subsidiary, HUGE Biopharma Australia Pty Ltd., have entered into an agreement with Ingenu CRO Pty Ltd. The agreement outlines a study to assess the safety and efficacy of unbuzzd(TM), a fortified oral liquid formula, being used as a treatment with healthy volunteers who are in an induced state of alcohol intoxication. According to the announcement, the trial is a key step in verifying that unbuzzd helps a person sober up faster from the effects of alcohol.…

Continue Reading

TuesdayFeb 20, 2024 1:33 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Market Offering Agreement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an agreement. The market offering agreement is with H.C. Wainwright & Co. LLC. According to the agreement, FSD Pharma may offer and sell Class B subordinate voting shares in the capital of the company at its discretion. The offering may total up to $11,154,232. The announcement also noted that Wainwright will receive a 3% cash commission on the gross proceeds of the offering. The sales of the Class B shares can be made whenever FSD…

Continue Reading

TuesdayFeb 06, 2024 12:37 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that the Court of Appeal for Ontario affirmed the judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. FSD Pharma was awarded an additional $5,000 in costs by the Court of Appeal in respect to Dr. Raza Bokhari’s failed motion for leave to appeal. The judgment confirmed arbitration awards in which the arbitrator dismissed…

Continue Reading

TuesdayJan 30, 2024 10:44 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Names New Board Member, Reports on Corporate Updates

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has appointed Dr. Sanjiv Chopra to its board of directors. According to the announcement. Chopra will be replacing Nitin Kaushal, who resigned from his position. A professor of medicine and former faculty dean for continuing medical education at Harvard Medical School, Dr. Sanjiv Chopra, MD, now serves as a Marshall Wolf Distinguished Clinician Educator at Brigham and Women's Hospital. A renowned speaker and author with more than 170 publications and 10 books to his credit, Chopra also serves…

Continue Reading

WednesdayJan 17, 2024 3:02 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement

Clearmind Medicine (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, has chosen Aegis Capital Corp. to act as sole bookrunner on its registered direct and private placement. According to the announcement, the placement is valued at $2.4 million. In the wealth management and investment banking business since 1984, Aegis is focused on providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. To view the full press release, visit https://ibn.fm/YmQUC About Clearmind…

Continue Reading

TuesdayJan 16, 2024 3:22 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Litigation

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today provided an update regarding its litigation with GBB Drink Lab Inc. (“GBB”). In May 2023, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations and filed a motion to dismiss the lawsuit. On Jan. 8, 2024, the court denied the motion to dismiss, which means only that FSD Pharma will now proceed with discovery. The company is confident that…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050